Literature DB >> 20890236

Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results.

Kyoko Fujita1, Mitsuko Yuzawa, Ryusaburou Mori.   

Abstract

BACKGROUND: To assess retinal sensitivity after photodynamic therapy (PDT) with half-dose verteporfin in patients with chronic central serous chorioretinopathy.
METHODS: Sixteen eyes with chronic chorioretinopathy treated using PDT with half-dose verteporfin were enrolled. Microperimetry covering the central area 12 degrees in diameter was performed before and at 1 month and 3 months after PDT. Retinal sensitivities within the retinal serous detachment before PDT, the PDT spot area, and the central area 2 degrees in diameter were evaluated.
RESULTS: Fourteen of 16 eyes showed complete resolution of retinal detachment at 3 months after PDT. Mean retinal sensitivities within the retinal serous detachment before and at 1 month and 3 months after PDT were 8.9 dB, 12.1 dB, and 14.7 dB, respectively. Mean retinal sensitivities within the PDT spot area were 11.0 dB, 14.2 dB, and 15.7 dB, respectively. Mean retinal sensitivities in the central area 2 degrees in diameter were 6.0 dB, 9.9 dB, and 12.5 dB, respectively. Mean retinal sensitivities at both 1 month and 3 months after PDT showed statistically significant improvements as compared with before PDT (both, P < 0.05).
CONCLUSION: Photodynamic therapy with half-dose verteporfin appears to be an effective and safe treatment for patients with chronic chorioretinopathy, improving retinal sensitivity for at least 3 months.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20890236     DOI: 10.1097/IAE.0b013e3181f049d3

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  18 in total

1.  Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  R Uetani; Y Ito; K Oiwa; K Ishikawa; H Terasaki
Journal:  Eye (Lond)       Date:  2012-05       Impact factor: 3.775

2.  Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes.

Authors:  S H Karakus; B Basarir; E Y Pinarci; E U Kirandi; A Demirok
Journal:  Eye (Lond)       Date:  2013-03-22       Impact factor: 3.775

Review 3.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

4.  Retinal sensitivity assessed by microperimetry and corresponding retinal structure and thickness in resolved central serous chorioretinopathy.

Authors:  H W Chung; C M Yun; J T Kim; S-W Kim; J Oh; K Huh
Journal:  Eye (Lond)       Date:  2014-08-01       Impact factor: 3.775

5.  Half-dose verteporfin combined with half-fluence photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Chun-Fu Liu; Lee-Jen Chen; Shawn H Tsai; Chi-Chun Lai; Wei-Chun Chan; Wei-Chi Wu; Nan-Kai Wang; Kuan-Jen Chen; Yih-Shiou Hwang; Yen-Po Chen; Ling Yeung
Journal:  J Ocul Pharmacol Ther       Date:  2014-03-05       Impact factor: 2.671

6.  Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Helena Vasconcelos; Inês Marques; A Rita Santos; Pedro Melo; Isabel Pires; João Figueira; José Faria de Abreu; M Luz Cachulo; Rufino Silva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-07       Impact factor: 3.117

Review 7.  Photodynamic therapy: current role in the treatment of chorioretinal conditions.

Authors:  D K Newman
Journal:  Eye (Lond)       Date:  2016-01-08       Impact factor: 3.775

8.  The effect of photodynamic therapy on macular sensitivity in eyes with acute central serous chorioretinopathy.

Authors:  Stefan Hagen; Siamak Ansari-Shahrezaei; Eva Smretschnig; Carl Glittenberg; Ilse Krebs; Alexandra Graf; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-08-29       Impact factor: 3.117

9.  Microperimetric evaluation of chronic central serous chorioretinopathy after half-dose photodynamic therapy.

Authors:  Kyoko Fujita; Kei Shinoda; Celso Soiti Matsumoto; Yutaka Imamura; Etsuko Tanaka; Yoshihiro Mizutani; Atsushi Mizota; Mitsuko Yuzawa
Journal:  Clin Ophthalmol       Date:  2012-10-16

10.  Emerging roles for antiangiogenesis factors in management of ocular disease.

Authors:  Muhammad Usman Saeed; Evangelia Gkaragkani; Kashif Ali
Journal:  Clin Ophthalmol       Date:  2013-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.